Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas

Z. Schroner, M. Javorský, J. Halušková, L. Klimčáková, E. Babjaková, M. Fabianová, E. Slabá, M. Kozárová, I. Tkáč

. 2012 ; 61 (2) : 177-183.

Jazyk angličtina Země Česko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12018940

The aim of the present pilot pharmacogenetic study was to analyse quantitative effects of sulphonylurea treatment in addition to metformin on parameters of glycemic control with respect to CDKAL1 genotypes in patients with type 2 diabetes. Effect of 6-month sulphonylurea therapy on glycemic control according to CDKAL1 genotypes was evaluated in 101 patients with type 2 diabetes who failed to achieve glycemic control on metformin monotherapy. CDKAL1 rs7756992 polymorphism was determined by melting curve analysis of small amplicon following real-time PCR. After sulphonylurea treatment fasting plasma glucose (FPG) levels were significantly different (p=0.045) among three CDKAL1 genotype groups (AA: n=49; AG: n=36; GG: n=16). In a dominant genetic model, carriers of the G-allele (AG+GG, n=52) achieved significantly lower FPG levels in comparison with patients with the AA genotype (6.90±1.08 vs. 7.48±1.12 mmol/l, p=0.013). Consequently, adjusted ΔFPG was significantly higher in the AG+GG compared to the AA group (1.48±1.51 vs. 1.02±1.33 mmol/l, p=0.022). Similar trend was observed for HbA1c levels, but the difference between the genotype groups did not reach the level of statistical significance. Relatively small number of included patients is a limitation of the present study. In conclusion, our results suggest that the magnitude of FPG reduction after 6-month sulphonylurea treatment in patients with type 2 diabetes is related to the variation in CDKAL1.

Citace poskytuje Crossref.org

Obsahuje 2 tabulky

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc12018940
003      
CZ-PrNML
005      
20180528142948.0
007      
ta
008      
120620s2012 xr f 000 0eng||
009      
AR
024    7_
$a 10.33549/physiolres.932228 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Schroner, Zbynek $7 xx0107722 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
245    10
$a Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas / $c Z. Schroner, M. Javorský, J. Halušková, L. Klimčáková, E. Babjaková, M. Fabianová, E. Slabá, M. Kozárová, I. Tkáč
500    __
$a Obsahuje 2 tabulky
504    __
$a Literatura $b 19
520    9_
$a The aim of the present pilot pharmacogenetic study was to analyse quantitative effects of sulphonylurea treatment in addition to metformin on parameters of glycemic control with respect to CDKAL1 genotypes in patients with type 2 diabetes. Effect of 6-month sulphonylurea therapy on glycemic control according to CDKAL1 genotypes was evaluated in 101 patients with type 2 diabetes who failed to achieve glycemic control on metformin monotherapy. CDKAL1 rs7756992 polymorphism was determined by melting curve analysis of small amplicon following real-time PCR. After sulphonylurea treatment fasting plasma glucose (FPG) levels were significantly different (p=0.045) among three CDKAL1 genotype groups (AA: n=49; AG: n=36; GG: n=16). In a dominant genetic model, carriers of the G-allele (AG+GG, n=52) achieved significantly lower FPG levels in comparison with patients with the AA genotype (6.90±1.08 vs. 7.48±1.12 mmol/l, p=0.013). Consequently, adjusted ΔFPG was significantly higher in the AG+GG compared to the AA group (1.48±1.51 vs. 1.02±1.33 mmol/l, p=0.022). Similar trend was observed for HbA1c levels, but the difference between the genotype groups did not reach the level of statistical significance. Relatively small number of included patients is a limitation of the present study. In conclusion, our results suggest that the magnitude of FPG reduction after 6-month sulphonylurea treatment in patients with type 2 diabetes is related to the variation in CDKAL1.
650    02
$a senioři $7 D000368
650    02
$a krevní glukóza $x analýza $7 D001786
650    02
$a cyklin-dependentní kinasa 5 $x genetika $7 D051360
650    02
$a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
650    02
$a ženské pohlaví $7 D005260
650    02
$a genetická variace $7 D014644
650    02
$a genotyp $7 D005838
650    02
$a lidé $7 D006801
650    02
$a hypoglykemika $x aplikace a dávkování $x terapeutické užití $7 D007004
650    02
$a mužské pohlaví $7 D008297
650    02
$a metformin $x aplikace a dávkování $x terapeutické užití $7 D008687
650    02
$a lidé středního věku $7 D008875
650    02
$a sulfonylmočovinové sloučeniny $x aplikace a dávkování $x terapeutické užití $7 D013453
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Javorský, Martin $7 xx0072695 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Halušková, Jana. $7 _AN053804 $u Department of Medical Biology, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Klimčáková, Lucia $7 xx0224570 $u Department of Medical Biology, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Babjaková, Eva. $7 xx0192766 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Fabianová, Martina. $7 xx0230917 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Slabáková, Eva $7 xx0125840 $u Department of Medical Biology, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Kozárová, Miriam. $7 xx0306259 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
700    1_
$a Tkáč, Ivan, $d 1958- $7 xx0073018 $u Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia
773    0_
$t Physiological research $x 0862-8408 $g Roč. 61, č. 2 (2012), s. 177-183 $w MED00003824
856    41
$u http://www.biomed.cas.cz/physiolres/archive.htm
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20120620071532 $b ABA008
991    __
$a 20180528143140 $b ABA008
999    __
$a ok $b bmc $g 912956 $s 776159
BAS    __
$a 3
BMC    __
$a 2012 $b 61 $c 2 $d 177-183 $i 0862-8408 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$a 2012-28/vtme

Najít záznam

Citační ukazatele

Možnosti archivace